Kansanterveyslaitos KTL

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Lindholm LH; Ibsen H; Dahlöf B; Devereux RB; Beevers G; de Faire U; Fyhrquist F; Julius S; Kjeldsen SE; Kristiansson K; Lederballe-Pedersen O; Nieminen MS; Omvik P; Oparil S; Wedel H; Aurup P; Edelman J; Snapinn S; LIFE Study Group; Tuomilehto J; Sarti C
Lancet (2002)

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Dahlöf B; Devereux RB; Kjeldsen SE; Julius S; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristansson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; for the LIFE Study Group; Tuomilehto J; Sarti C; Ylihärsilä H
Lancet : 9311 (2002)

Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE Study

Dahlöf B; Devereux RB; Julius S; Kjeldsen SE; Beevers G; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; LIFE Study Group; Tuomilehto J; Sarti C
Hypertension (1998)

Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial – lipid-lowering arm (ASCOT-LLA)

Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B; on begalf of the ASCOT investigators (Tuomilehto J; Valle T)
European Journal of Cardiovascular Prevention and Rehabilitation (2005)

Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients. The Losartan Intervention For Endpoints (LIFE). Reduction in Hypertension Study

Okin PM; Jern S; Devereux RB; Kjeldsen SE; Dahlöf B; LIFE Study Group; Sarti C; Tuomilehto J
Hypertension (2000)

Effects of Losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losarthan Intervention For Endpoint Reduction (LIFE) Substudy

Kjeldsen SE; Dahlöf B; Devereux RB; Julius S; Aurup P; Edelman J; Beevers G; De Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H; for the LIFE Study Group; Sarti C; Tuomilehto J; Ylihärsilä H
JAMA (2003)

Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population. The LIFE Study

Wachtell K; Bella JN; Liebson PR; Gerdts E; Dahlöf B; Aalto T; Roman MJ; Papademetriou V; Ibsen H; Rokkedal J; Devereux RB; Sarti C; Tuomilehto J
Hypertension (2000)

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering rm (ASCOT-LLA): a multi

Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Östergren J; ASCOT Investigators; Sarti C; Tuomilehto J; Valle T
Lancet (2003)

Rationale, design, methods and baseline demography of participants of th Anglo-Scandinavian Cardiac Outcomes Trial

Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J; The ASCOT investigators; Sarti C; Tuomilehto J; Valle T
J Hypertens : 6 (2001)

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)

Sever PS; Poulter NR; Dahlöf B; Wedel H; Collins R; Beevers G; Caulfield M; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; Östergren J; (Tuomilehto J; Valle T)
Diabetes Care (2005)

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)

Poulter NR; Wedel H; Dahlöf B; Sever PS; Beevers DG; Caulfield M; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; Östergren J; Pocock S; for the ASCOT Investigators; (Tuomilehto J)
Lancet (2005)

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

Hoieggen A; Alderman MH; Kjeldsen SE; Julius S; Devereux RB; De Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederball-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Chen C; Dahlöf B; LIFE Study Group; Sarti C; Tuomilehto J; Ylihärsilä H
Kidney Int (2004)

The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study. Rationale, Design and Methods

Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; The LIFE Study Group; Tuomilehto J; Sarti C
AM J HYPERTENS : 7 (1997)

"Dahlöf B" - Selaus tekijän mukaan Kansanterveyslaitos KTL

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol ﻿

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol ﻿

Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE Study ﻿

Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial – lipid-lowering arm (ASCOT-LLA) ﻿

Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients. The Losartan Intervention For Endpoints (LIFE). Reduction in Hypertension Study ﻿

Effects of Losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losarthan Intervention For Endpoint Reduction (LIFE) Substudy ﻿

Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population. The LIFE Study ﻿

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering rm (ASCOT-LLA): a multi ﻿

Rationale, design, methods and baseline demography of participants of th Anglo-Scandinavian Cardiac Outcomes Trial ﻿

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA) ﻿

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) ﻿

The impact of serum uric acid on cardiovascular outcomes in the LIFE study ﻿

The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study. Rationale, Design and Methods ﻿